Satsuma Pharmaceuticals Inc. (STSA)

Name: Satsuma Pharmaceuticals Inc. (STSA) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Satsuma Pharmaceuticals Inc. (STSA)

Stock Card

$1.10

$0.00 (0.00%)

As on 09-Jun-2023 09:30EDT

Market cap

$37 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

0.4

Div. Yield

0 %

Satsuma Pharmaceuticals (STSA) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 1.10 High: 1.10

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-31 Mln
ROE

-1 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

0.6
Debt to Equity

0
Book Value

$--
EPS

$-2
Face value

--
Shares outstanding

33,152,500

10 Years Aggregate

CFO

$235.01 Mln

EBITDA

$-196.18 Mln

Net Profit

$-114.58 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Satsuma Pharmaceuticals (STSA)	22.2	1.9	24.0	-67.6	-66.2	--	--
BSE Sensex^*	-9.6	-2.0	3.1	-4.7	5.4	6.0	10.4

As on 09-Jun-2023 | *As on 02-Sep-2026

Company	2022	2021	2020
Satsuma Pharmaceuticals (STSA)	-80.0	-2.4	-76.6
BSE Sensex	4.4	22.0	15.8
BSE Sensex	4.4	22.0	15.8

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Satsuma Pharmaceuticals (STSA)	1.1	36.8	0.0	-63.3	--	-119.5	--	0.4
Arrowhead Pharmaceuticals (ARWR)	82.7	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Cytokinetics Inc (CYTK)	71.4	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	56.9	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	107.7	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	363.8	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	538.7	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	583.2	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	353.4	9,625.4	0.0	-339.1	--	-30.6	--	7.6
Protagonist Therapeutics (PTGX)	146.5	9,339.4	282.0	82.9	-28.6	11.4	140.1	11.5

Shareholding Pattern

View Details

About Satsuma Pharmaceuticals (STSA)

Satsuma Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops novel therapeutic products for the acute treatment of migraines. The company's product candidature includes STS101, a drug-device combination of a proprietary... dry-powder formulation of dihydroergotamine mesylate, which can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. As of June 8, 2023, Satsuma Pharmaceuticals, Inc. operates as a subsidiary of Shin Nippon Biomedical Laboratories, Ltd. Read more

Pres, CEO & Director

Mr. John A. Kollins MBA
Pres, CEO & Director

Mr. John A. Kollins MBA
Headquarters

South San Francisco, CA
Website

https://www.satsumarx.com

FAQs for Satsuma Pharmaceuticals (STSA)

What is the current share price of Satsuma Pharmaceuticals Inc (STSA) Today?

The share price of Satsuma Pharmaceuticals Inc (STSA) is $1.10 (NASDAQ) as of 09-Jun-2023 09:30 EDT. Satsuma Pharmaceuticals Inc (STSA) has given a return of -66.17% in the last 3 years.

What is the current PB & PE ratio of Satsuma Pharmaceuticals Inc (STSA)?

Since, TTM earnings of Satsuma Pharmaceuticals Inc (STSA) is negative, P/E ratio is not available.
The P/B ratio of Satsuma Pharmaceuticals Inc (STSA) is 0.42 times as on 09-Jun-2023, a 92 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2022	-0.42	-0.14
2021	-2.55	1.29
2020	-1.66	-0.87
2019	-4.21	-2.75
2018	--	--

What is the 52 Week High and Low of Satsuma Pharmaceuticals Inc (STSA)?

The 52-week high and low of Satsuma Pharmaceuticals Inc (STSA) are Rs -- and Rs -- as of 02-Sep-2026.

What is the market cap of Satsuma Pharmaceuticals Inc (STSA)?

Satsuma Pharmaceuticals Inc (STSA) has a market capitalisation of $ 37 Mln as on 09-Jun-2023. As per SEBI classification, it is a company.

Should I invest in Satsuma Pharmaceuticals Inc (STSA)?

Before investing in Satsuma Pharmaceuticals Inc (STSA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.